Hypertension in pregnancy - Treatment and after-care;Schwangerschaftshypertonie: Therapie und nachsorge

Journal fur Hypertonie

Volumn 12, Issue 3, 2008, Pages 7-12

  Homuth, Volker ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CAPTOPRIL; DIHYDRALAZINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; MAGNESIUM SULFATE; METHYLDOPA; METOPROLOL; NIFEDIPINE; NITRENDIPINE; PHENYTOIN; THIAZIDE DIURETIC AGENT; URAPIDIL; VERAPAMIL;

AFTERCARE; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; BLOOD PRESSURE REGULATION; BREAST FEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CONTINUOUS INFUSION; DISEASE ACTIVITY; DISEASE PREDISPOSITION; DYSLIPIDEMIA; EMERGENCY CARE; ENDOTHELIAL DYSFUNCTION; EPIDEMIOLOGICAL DATA; FETUS DISEASE; FETUS MORTALITY; FOLLOW UP; GROWTH RETARDATION; HEART INFARCTION; HEMODYNAMICS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; MATERNAL DISEASE; MATERNAL HYPERTENSION; MATERNAL MORTALITY; METABOLIC SYNDROME X; NEWBORN DEATH; OBESITY; PATIENT COUNSELING; PREECLAMPSIA; PREGNANCY COMPLICATION; PREMATURITY; PROPHYLAXIS; PROTEINURIA; STROKE; THROMBOPHILIA; VASCULAR DISEASE; VASCULAR HYPERTONIA;

EID: 52249115390     PISSN: 10282327     EISSN: 16809378     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Leitlinien für Diagnostik und Therapie der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG). Diagnostik und Therapie hypertensiver Schwangerschaftserkrankungen. Erarbeitungsdatum 02/2007. AWMF-online Nr. 015/018. http: //www.uniduesseldorf.de/AWMF/11/015-018.htm
2. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005.
3. Davison JM, Homuth V, Jeyabalan A, Conrad KP, Karumanchi SA, Quaggin S, Dechend R, Luft FC. New aspects in the pathophysiology of preeclampsia. J Am Soc Nephrol 2004; 15: 2440-8.
4. Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi SA, Lim KH. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol 2007; 197: 28.e1-28.e6.
5. Stepan H, Geipel A, Schwarz F, Krämer T, Wessel N, Faber R. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol 2008; 198: 175.e1-175.e6.
6. National High Blood Pressure Education Program. Working group report on high blood pressure in pregnancy. Am J Obstet Gynecol 2000; 183: S1-S22.
7. von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 2000; 355: 87-92.
8. nd ed. Appleton & Lange, Stamford, CN, 1999: 69-102.
9. Barker DJ, Osmond C, Golding J, Kuh D, Wadsworth ME. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. Br Med J 1989; 298: 564-7.
10. Lawlor DA, Ronalds G, Clark H, Smith GD, Leon DA. Birth weight is inversely associated with incident coronary heart disease and stroke among individuals born in the 1950s. Findings from the Aberdeen children of the 1950s prospective cohort study. Circulation 2005; 112: 1414-8.
11. Skilton MR, Evans N, Griffith KA, Harmer JA, Celermajer DS. Aortic wall thickness in newborns with intrauterine growth restriction. Lancet 2005; 365: 1444-6.
12. Norman M, Martin H. Preterm birth attenuates association between low birth weight and endothelial dysfunction. Circulation 2003; 108: 996-1001.
13. Homuth V. Hypertonie in der Schwangerschaft und Stillzeit. Notfall & Hausarztmedizin 2005; 31: 167-73.
14. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369: 1791-8.
15. Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 2006: 367: 1145-54.
16. Rumbold AR, Crowther CA, Haslam RR, Dekker GA, Robinson JS; ACTS Study Group. Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med 2006; 354: 1796-806.
17. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley BS, Dyer S, Gideon PS, Hall K, Ray WA. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354: 2443-51.
18. Rath W. Das HELLP-Syndrom. In: Heilmann L, Rath W (Hrsg). Schwangerschaftshochdruck. Wissenschaftliche Verlagsgesellschaft mbh, Stuttgart, 2002; 236-55.
19. Ito S. Drug therapy for breast-feeding women. N Engl J Med 2000; 343: 118-26.
20. Caspi A, Williams B, Kim-Cohen J, Craig IW, Milne BJ, Poulton R, Schalkwyk LC, Taylor A, Werts H, Moffitt TE. Moderation of breastfeeding effects on the IQ by genetic variation in fatty acid metabolism. Proc Natl Acad Sci USA 2007; 104: 18860-5.
21. Schaefer C, Spielmann H, Vetter K. Arzneiverordnung in Schwangerschaft und Stillzeit. 7. Aufl. Verlag Urban & Fischer, München-Jena, 2006.
22. Harskamp RE, Zeeman GG. Preeclampsia: at risk for remote cardiovascular disease. Am J Med Sci 2007; 334: 291-5.
23. Luft FC. Pre-eclampsia and the maternal cardiovascular risk. Nephrol Dial Transplant 2003; 18: 860-1.